via University of Pittsburgh School of Medicine
Today in Science, researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat COVID-19.
These special llama antibodies, called “nanobodies,” are much smaller than human antibodies and many times more effective at neutralizing the SARS-CoV-2 virus. They’re also much more stable.
“Nature is our best inventor,” said senior author Yi Shi, Ph.D., assistant professor of cell biology at Pitt. “The technology we developed surveys SARS-CoV-2 neutralizing nanobodies at an unprecedented scale, which allowed us to quickly discover thousands of nanobodies with unrivaled affinity and specificity.”
To generate these nanobodies, Shi turned to a black llama named Wally—who resembles and therefore shares his moniker with Shi’s black Labrador.
Shi and colleagues immunized the llama with a piece of the SARS-CoV-2 spike protein and, after about two months, the animal’s immune system produced mature nanobodies against the virus.
Using a mass spectrometry-based technique that Shi has been perfecting for the past three years, lead author Yufei Xiang, a research assistant in Shi’s lab, identified the nanobodies in Wally’s blood that bind to SARS-CoV-2 most strongly.
Then, with the help of Pitt’s Center for Vaccine Research (CVR), the scientists exposed their nanobodies to live SARS-CoV-2 virus and found that just a fraction of a nanogram could neutralize enough virus to spare a million cells from being infected.
These nanobodies represent some of the most effective therapeutic antibody candidates for SARS-CoV-2, hundreds to thousands of times more effective than other llama nanobodies discovered through the same phage display methods used for decades to fish for human monoclonal antibodies.
Shi’s nanobodies can sit at room temperature for six weeks and tolerate being fashioned into an inhalable mist to deliver antiviral therapy directly into the lungs where they’re most needed. Since SARS-CoV-2 is a respiratory virus, the nanobodies could find and latch onto it in the respiratory system, before it even has a chance to do damage.
In contrast, traditional SARS-CoV-2 antibodies require an IV, which dilutes the product throughout the body, necessitating a much larger dose and costing patients and insurers around $100,000 per treatment course.
“Nanobodies could potentially cost much less,” said Shi. “They’re ideal for addressing the urgency and magnitude of the current crisis.”
In collaboration with Cheng Zhang, Ph.D., at Pitt, and Dina Schneidman-Duhovny, Ph.D., at the Hebrew University of Jerusalem, the team found that their nanobodies use a variety of mechanisms to block SARS-CoV-2 infection. This makes nanobodies ripe for bioengineering. For instance, nanobodies that bind to different regions on the SARS-CoV-2 virus can be linked together, like a Swiss army knife, in case one part of the virus mutates and becomes drug-resistant.
“As a virologist, it’s incredible to see how harnessing the quirkiness of llama antibody generation can be translated into the creation of a potent nanoweapon against clinical isolates of SARS-CoV-2,” said study coauthor and CVR Director Paul Duprex, Ph.D.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Llama nanobodies
- Meta unveils Llama 3, claims it’s the ‘most capable’ open LLM
Meta claims Llama 3 is a ‘major leap’ from its predecessor and ‘on par’ with the best options on the market. Meta is attempting to gain an edge in the AI rat race with the release of Llama ...
- New Llama 3 LLM AI model released by Meta AI
Meta’s recent unveiling of Llama 3, a new state-of-the-art large language model, signifies a groundbreaking leap forward in the realm of artificial intelligence. This powerful model comes in two ...
- Meta eyes LLM dominance with new Llama 3 models
Facebook, Instagram, and WhatsApp parent Meta has released a new generation of its open source Llama large language model (LLM) in order to garner a bigger pie of the generative AI market by ...
- Did Meta Just Top ChatGPT With Its Release of Llama 3's Meta AI?
Last year, Facebook parent company Meta entered the AI development race by launching Llama 2. This week, Meta launched an updated Llama — Llama 3 — and added its latest large language model ...
- Mark Zuckerberg’s Meta releases early versions of Llama 3 AI model in bid to catch ChatGPT
Meta Platforms on Thursday released early versions of its latest large language model, Llama 3, and an image generator that updates pictures in real time while users type prompts, as it races to ...
Go deeper with Google Headlines on:
Llama nanobodies
[google_news title=”” keyword=”llama nanobodies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Inhalable therapeutics to prevent and treat COVID-19
- Can Neosporin Protect You From Getting COVID-19?
A small study recently published in PNAS presents a similar, if lower-tech, idea. Coating the inside of the nose with the over-the-counter antibiotic ointment Neosporin seems to trigger an immune ...
- Study: Antibiotic use in moderate COVID-19 linked to clinical deterioration
Antibiotic treatment of adults hospitalized with moderate COVID-19 is associated with clinical deterioration, despite the drugs being given to over 40% of patients, according to new research being ...
- Analysis finds significant variations in national COVID-19 treatment recommendations
National clinical guidelines for the treatment of COVID-19 vary significantly around the world, with under-resourced countries the most likely to diverge from gold standard (World Health Organization; ...
- Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms 1. David Cutler, PhD, a professor of economics at Harvard University, estimates in a recent research disclosure that the ...
- Coronavirus and COVID-19: All Articles, Videos and Resources
While mRNA vaccines have caused rare cases of myocarditis, a CDC analysis found no connection between getting jabbed and sudden cardiac death.
Go deeper with Google Headlines on:
Inhalable therapeutics to prevent and treat COVID-19
[google_news title=”” keyword=”inhalable therapeutics to prevent and treat COVID-19″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]